Fulgent Genetics Inc

Fulgent Genetics Inc

FLGT

Get informed when a big investor buys or sells

+ Follow
Market Cap$543.59M
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Fulgent Genetics IncFulgent Genetics Inc-6.8--8%1.70.1
$17.00

Target Price by Analysts

8.8% downsideFulgent Genetics Target Price DetailsTarget Price
$7.55

Current Fair Value

59.5% downside

Overvalued by 59.5% based on the discounted cash flow analysis.

Share Statistics

Market cap$543.59 Million
Enterprise Value$657.14 Million
Dividend Yield$- (-)
Earnings per Share$-1.97
Beta0.89
Outstanding Shares28,005,000

Return

Return on Equity-8.42%ROE
Return on Assets-7.75%
Return on Invested Capital-9.99%

Valuation & Multiples

P/E Ratio-6.79P/E Ratio
PEG-12.17PEG
Price to Sales1.7Price to Sales
Price to Book Ratio0.53Price to Book Ratio
Enterprise Value to Revenue2.03
Enterprise Value to EBIT-6.46
Enterprise Value to Net Income-8
Total Debt to Enterprise0.21
Debt to Equity0.14Debt to Equity

Revenue Sources

No data

Insider Trades

Last Earnings Call

Report Date
August 7, 2026
EPS Estimate
$-0.26
Average shareholder expectation
Revenue Estimate
$89.95 M
Average shareholder expectation

Next Earnings Call

Expected Date
November 6, 2026
EPS Estimate
$-0.65
Average shareholder expectation
Revenue Estimate
$86.30 M
Average shareholder expectation

Institutional Put/Call Ratio

Market sentiment based on institutional option activity.

Put/Call Ratio0.0000 41.54%
Total Calls- 100.00%
Total Puts- 100.00%

Institutional Ownership

Holdings and activity of institutional investors.

Ownership %12.31% 44.39%
Total Invested$78.03M 71.88%
Investors Holding46 115.00%

ESG Score

No data

About Fulgent Genetics Inc

429 employees
CEO: Ming Hsieh

Fulgent Genetics' proprietary technology platform has created a broad, flexible test menu and the ability to continually expand and improve its proprietary genetic reference library while maintaining accessible pricing, high accuracy and...